Featured Dataverses

In order to use this feature you must have at least one published or linked dataverse.

Publish Dataverse

Are you sure you want to publish your dataverse? Once you do so it must remain published.

Publish Dataverse

This dataverse cannot be published because the dataverse it is in has not been published.

Delete Dataverse

Are you sure you want to delete your dataverse? You cannot undelete this dataverse.

Advanced Search

61 to 70 of 234 Results
GROUP 3 CRF 190516 (003)mh.pdf
Sep 7, 2023 - Data for: A Phase 1b, open-label, age de-escalation, dose-escalation study to evaluate the safety and immunogenicity of different doses of a candidate malaria vaccine; adjuvanted R21(R21/MM) in adults, young children and infants in Kilifi, Kenya
Adobe PDF - 1.8 MB - MD5: c70718f59ae9eb65e3bde6f795f98a5f
Case Report Form
210204_Adendum 1.2_English Adult ICF_ Version 1.8-Clean.pdf
210204_Adendum 1.2_English Adult ICF_ Version 1.8-Clean.pdf
Jul 25, 2023 - Data for: A Phase 1b, open-label, age de-escalation, dose-escalation study to evaluate the safety and immunogenicity of different doses of a candidate malaria vaccine; adjuvanted R21(R21/MM) in adults, young children and infants in Kilifi, Kenya
Adobe PDF - 248.6 KB - MD5: 433c34b505ef5fdca9ec1c2dee38d9d4
Informed Consent Form (ICF)
Child and Infant ENGLISH ICF version 1.8_Highlighted 27March.pdf
Child and Infant ENGLISH ICF version 1.8_Highlighted 27March.pdf
Jul 25, 2023 - Data for: A Phase 1b, open-label, age de-escalation, dose-escalation study to evaluate the safety and immunogenicity of different doses of a candidate malaria vaccine; adjuvanted R21(R21/MM) in adults, young children and infants in Kilifi, Kenya
Adobe PDF - 304.8 KB - MD5: ee1c82040f4ce26b0762a5fff5ed8589
Informed Consent Form (ICF)
VAC073(R21-MM)_Statistical_Analytical Plan (003).pdf
Jul 25, 2023 - Data for: A Phase 1b, open-label, age de-escalation, dose-escalation study to evaluate the safety and immunogenicity of different doses of a candidate malaria vaccine; adjuvanted R21(R21/MM) in adults, young children and infants in Kilifi, Kenya
Adobe PDF - 1.2 MB - MD5: a82b962d7d6dae05565f65e0dcbbb652
Statistical Analysis Plan (SAP)
210125_VAC073 Protocol Version 2.3_Clean.pdf
Jul 25, 2023 - Data for: A Phase 1b, open-label, age de-escalation, dose-escalation study to evaluate the safety and immunogenicity of different doses of a candidate malaria vaccine; adjuvanted R21(R21/MM) in adults, young children and infants in Kilifi, Kenya
Adobe PDF - 1.3 MB - MD5: 3dbda8b46b31a8b2e437162baf46799b
Study Protocol
childaes_anon.tab
Jul 25, 2023 - Data for: A Phase 1b, open-label, age de-escalation, dose-escalation study to evaluate the safety and immunogenicity of different doses of a candidate malaria vaccine; adjuvanted R21(R21/MM) in adults, young children and infants in Kilifi, Kenya
Tabular Data - 607.6 KB - 26 Variables, 2208 Observations - UNF:6:/CiyIZa9zxcIZb+d7qjM/A==
csvData
Children and Infants Solicited Adverse events(local+systemic).
demographics_anon.tab
Jul 25, 2023 - Data for: A Phase 1b, open-label, age de-escalation, dose-escalation study to evaluate the safety and immunogenicity of different doses of a candidate malaria vaccine; adjuvanted R21(R21/MM) in adults, young children and infants in Kilifi, Kenya
Tabular Data - 19.9 KB - 18 Variables, 188 Observations - UNF:6:NUpKg4sQH8XFBdBF1XjefQ==
csvData
Demographic information of participants at screening.
immunologydata.tab
Jul 25, 2023 - Data for: A Phase 1b, open-label, age de-escalation, dose-escalation study to evaluate the safety and immunogenicity of different doses of a candidate malaria vaccine; adjuvanted R21(R21/MM) in adults, young children and infants in Kilifi, Kenya
Tabular Data - 34.3 KB - 5 Variables, 981 Observations - UNF:6:BF467KZ6CTpbOps+CnX7pQ==
csvData
Immunology data at all immunological study timepoints.
inclusion.tab
Jul 25, 2023 - Data for: A Phase 1b, open-label, age de-escalation, dose-escalation study to evaluate the safety and immunogenicity of different doses of a candidate malaria vaccine; adjuvanted R21(R21/MM) in adults, young children and infants in Kilifi, Kenya
Tabular Data - 51.3 KB - 22 Variables, 398 Observations - UNF:6:5ZIEti3B2W5fKefzZcQrXQ==
csvData
Inclusion criteria for participants before dosing.
localaes.tab
Jul 25, 2023 - Data for: A Phase 1b, open-label, age de-escalation, dose-escalation study to evaluate the safety and immunogenicity of different doses of a candidate malaria vaccine; adjuvanted R21(R21/MM) in adults, young children and infants in Kilifi, Kenya
Tabular Data - 118.7 KB - 22 Variables, 550 Observations - UNF:6:X8jY33Lj0poVg1HbrxsCEw==
csvData
Adult Local solicited adverse events
Add Data

Sign up or log in to create a dataverse or add a dataset.

Sign Up Log In
Share Dataverse

Share this dataverse on your favorite social media networks.

Link Dataverse
Reset Modifications

Are you sure you want to reset the selected metadata fields? If you do this, any customizations (hidden, required, optional) you have done will no longer appear.